Bone metastases represent a formidable complication in advanced cancer, often resulting in severe pain, skeletal instability and a diminished quality of life. In recent years, significant progress has ...
For more information about Syncromune®, Inc. please visit www.syncromune.com.
ROBOMET Revisited: Is Stereotactic Body Radiotherapy Truly Effective for Painful Bone Metastases? The following represents disclosure information provided by authors of this manuscript. All ...
The Article by Tamim Niazi and colleagues1 on the Prostate Cancer Study 9 (PCS-9) investigated stereotactic body radiotherapy ...
Dervis, A. (2025) Curative Outcome of Osteosarcoma with Associated Pleural Effusion: A Case Report —Bone Tumor with Pleural ...
Reply to: “Beyond 1 Month: A Broader Look at the ROBOMET Trial Results” and “ROBOMET Revisited: Is Stereotactic Body Radiotherapy Truly Effective for Painful Bone Metastases?” The following represents ...
The FDA has approved Osvyrti (denosumab-desu), a biosimilar to Prolia (denosumab), and Jubereq (denosumab-desu), a biosimilar to Xgeva (denosumab).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback